Literature DB >> 12430888

The role of the EBMT activity survey in the management of hematopoietic stem cell transplantation. European Group for Blood Marrow Treansplantation.

Alois Gratwohl1.   

Abstract

Disease or treatment oriented registries form an integral part of modern medicine. They complement industry driven, corporate group sponsored and institutional research and are, together with prospective randomised trials cornerstones of modern evidence based medicine. Focus has been on rapid collection, analysis and dissemination of information on rare procedures with stress on patient outcome. In complex expensive procedures, such as hematopoietic stem cell transplants (HSCT), novel structures are required to catch outcome at team or national level. The annual activity survey of the European Group for Blood and Marrow Transplants EBMT forms such an instrument. Since 1990, EBMT has been collecting, on an annual basis, numbers of HSCT from the preceding year according to indication, donor type and stem cell source. The survey covers all European countries. In 1990, 143 teams reported 4,234 HSCT; in the year 2000, 619 teams reported 19,136 HSCT (33% allogeneic, 67% autologous). This information, which covers over 90% of all HSCT performed in Europe and is based on 132,963 HSCT (33% allogeneic, 67% autologous), gives a clear overview of current status and ongoing trends. It shows the general increase in HSCT from 1990 to 2000 with few exceptions, such as autologous HSCT for breast cancer and allogeneic HSCT for chronic myeloid leukemia. It illustrates the shift in technology from bone marrow as stem cell source in 1990 (100%) to peripheral blood in 2000 (96% of autologous, 53% of allogeneic HSCT). Supplemented by population data and economic factors (Gross national Product, Health Care Expenditures, Health Care systems) of the individual countries it allows comparison of transplant rates (Number of transplants per 10 million inhabitants), team densities (Number of transplant teams per 10 million inhabitants) and trends between countries. It permits quantification of the impact of economics and health care systems and provides a basis for quality control and allows assessment of the main factors influencing team decisions: evidence, disease prevalence, economics and expectations. As such, it is an essential tool for patient counselling and health care planning.

Entities:  

Mesh:

Year:  2002        PMID: 12430888     DOI: 10.1007/bf03165290

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  11 in total

Review 1.  Stem cell transplantation.

Authors:  A L Lennard; G H Jackson
Journal:  BMJ       Date:  2000-08-12

2.  Economics, health care systems and utilization of haematopoietic stem cell transplants in Europe.

Authors:  Alois Gratwohl; Jakob Passweg; Helen Baldomero; Bruno Horisberger; Alvaro Urbano-Ispizua
Journal:  Br J Haematol       Date:  2002-05       Impact factor: 6.998

3.  Transplantation in chronic myeloid leukaemia.

Authors:  A Gratwohl; H Baldomero; A Urbano-Ispizua
Journal:  Lancet       Date:  2002-02-23       Impact factor: 79.321

4.  Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation.

Authors:  J M Goldman; N Schmitz; D Niethammer; A Gratwohl
Journal:  Bone Marrow Transplant       Date:  1998-01       Impact factor: 5.483

5.  Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group.

Authors:  E Gluckman; V Rocha; A Boyer-Chammard; F Locatelli; W Arcese; R Pasquini; J Ortega; G Souillet; E Ferreira; J P Laporte; M Fernandez; C Chastang
Journal:  N Engl J Med       Date:  1997-08-07       Impact factor: 91.245

Review 6.  Unrelated marrow donor registries.

Authors:  D L Confer
Journal:  Curr Opin Hematol       Date:  1997-11       Impact factor: 3.284

7.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.

Authors:  W I Bensinger; P J Martin; B Storer; R Clift; S J Forman; R Negrin; A Kashyap; M E Flowers; K Lilleby; T R Chauncey; R Storb; F R Appelbaum
Journal:  N Engl J Med       Date:  2001-01-18       Impact factor: 91.245

8.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

9.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Authors:  B J Druker; C L Sawyers; H Kantarjian; D J Resta; S F Reese; J M Ford; R Capdeville; M Talpaz
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

10.  Bone marrow transplantation activity in Europe 1990. European Group for Bone Marrow Transplantation (EBMT)

Authors:  A Gratwohl
Journal:  Bone Marrow Transplant       Date:  1991-09       Impact factor: 5.483

View more
  3 in total

1.  Demographic Changes: The Impact for Safe Blood Supply.

Authors:  Andreas Greinacher; Konstanze Fendrich; Wolfgang Hoffmann
Journal:  Transfus Med Hemother       Date:  2010-05-20       Impact factor: 3.747

2.  Time limitations and the challenge of providing infection-preventing dental care to hematopoietic stem-cell transplantation patients.

Authors:  Sharon Elad; Adi A Garfunkel; Reuven Or; Eli Michaeli; Michael Y Shapira; Dan Galili
Journal:  Support Care Cancer       Date:  2003-07-18       Impact factor: 3.603

3.  Quality control and assurance in hematopoietic stem cell transplantation data registries in Japan and other countries.

Authors:  Yachiyo Kuwatsuka
Journal:  Int J Hematol       Date:  2015-11-13       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.